Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Truist

Trex's Price Target Cut By Several Analysts After Q2 Results

Barclays analyst Matthew Bouley lowered the price target for Trex Company Inc (NYSE:TREX) to $53 (a downside of 2.7%) from $63 while maintaining the Equal Weight ratings on the shares. The analyst stated that while de-stocking was anticipated by investors following AZEK Company Inc. (NYSE:AZEK) report, the magnitude of the impact on TREX's sales in 2022 with subsequent gross…

Benzinga

For Truist Ventures, 'Self-Awareness' And 'Strategy' Are Core To Innovating Across Key Themes

In light of an uncertain market environment, some popular outlets have voiced concern over the two-decade venture capital bull run.

Benzinga

Analysts Cut GMS Price Target Post Q4 Results

Raymond James analyst Sam J. Darkatsh lowered the price target for GMS Inc (NYSE:GMS) to $70 (61% upside) from $72 while maintaining the Outperform rating on the shares. The analyst mentions that GMS trades at a double-digit FCF yield; has seen recent insider buying with expanded repo authority; has a "drama-free" balance sheet, and has…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Juneteenth so far only partially embraced by private sector

Juneteenth is a relatively new holiday, and private firms are in varying stages of embracing it.

Tribune News Service

Read How Analysts Reacted To Devon Energy's RimRock Transaction

Mizuho Securities analyst Vincent Lovaglio raised the price target for Devon Energy Corp (NYSE:DVN) to $94 (an upside of 28%) from $92, reflecting the $865 million Rim Rock acquisition. The analyst states that the transaction adds 15kboed and 38k net acres to the company's existing 48kboed and 85k net acre Bakken position at ~4x free cash…

Benzinga

Here's What Analysts Had To Say About GitLab Post Q1 Beat

Analysts acknowledged GitLab Inc's (NASDAQ:GTLB) Q1 beat by re-rating the stock. RBC Capital analyst Matthew Hedberg maintained GitLab with an Outperform and raised the price target from $64 to $66. GitLab reported a solid start to the year as execution continued in its third quarter as a public company, Hedberg noted. Revenue growth again accelerated while RPO…

Benzinga

Read How Analysts Reacted To Jack In The Box's Q2 Results

Analysts lowered the price target of Jack In The Box Inc (NASDAQ:JACK) following the company's Q2 results. Wedbush analyst Nick Setyan lowered the price target to $90 (35% upside) from $110 and maintained Outperform rating on the stock. The analyst thinks JACK's current valuation discounts an overly pessimistic view of the management's ability to…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Executives Buy Around $3.5M Of 2 Stocks

Although Dow Jones futures traded sharply lower this morning on Monday, there were a few notable insider trades.

Benzinga

Another Analyst Sets Bullish Tone On NVIDIA, Sees Considerable Upside

New Street analyst Pierre Ferragu upgraded NVIDIA Corp (NASDAQ:NVDA) to Buy from Neutral with a price target of $280 (30.2% upside). Ferragu saw an attractive valuation, greater visibility on the "crypto-winter risk," and the company's robust data center outlook. Ethereum's hash rate quadrupled between October 2020 and January 2022, likely boosting Nvidia's FY22 gaming revenues…

Benzinga

Here's Why BofA Views Nvidia As Leading Growth Company In Semis

BofA analyst Vivek Arya reiterated a Buy rating and a $375 price target (71.1% upside) on NVIDIA Corp (NASDAQ:NVDA) and a Top Pick designation. Arya saw the Baird downgrade-related selloff as likely done. Truist also slashed the price targets on the chipmakers. Arya acknowledged that Nvidia's gaming business was vulnerable to weaker demand from Europe due to the Russia-Ukraine…

Benzinga

Another Analyst Gets Cautious Ahead Of Netflix's Q1 After Baird, Stifel

Truist analyst Matthew Thornton lowered the price target on Netflix Inc (NASDAQ: NFLX) to $409 from $470 ahead of its Q1 results. The price target implied an upside of 17.5%.

Benzinga

Nvidia Shares Drop As Baird Cuts Price Target By 38%; Downgrades To Neutral

Baird analyst Tristan Gerra downgraded NVIDIA Corp (NASDAQ:NVDA) to Neutral from Outperform with a price target of $225, down from $360. The price target implied a downside of 2.7%. Gerra contended that order cancellations recently started in consumer GPUs due to excess inventories, a slowdown in consumer demand and PC demand, and the Russia embargo. Also…

Benzinga

Here's Why Truist Slashed Price Targets On AMD, Intel, Nvidia

Truist analyst William Stein warned against the sustained semiconductor rally due to a sudden negative shift in demand signals from a wide swath of computer, consumer, and communications OEMs to at least some of their semi-suppliers. The cuts mainly related to production in the second quarter, but demand throughout the…

Benzinga

Analysts Bump Up Costco Price Target Post March Sales Results

Truist analyst Scot Ciccarelli raised the price target on Costco Wholesale Corp (NASDAQ: COST) to $634 from $603 and kept a Buy rating on the shares.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Read How Analysts Reacted To Blend Labs' Q4 Results

Analysts mainly slashed the price targets or downgraded the rating on Blend Labs Inc (NYSE:BLND) post Q4 results. KeyBanc analyst Josh Beck lowered the price target to $6 from $10 (26% upside) and kept an Overweight. The company's FY22 revenue forecast was well below the Street's $343.8 million, reflecting the negative impact of higher rates…

Benzinga

Why Did Truist Lower IGM Biosciences' Price Target?

Truist has lowered the price target on IGM Biosciences Inc (NASDAQ:IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA (NASDAQ:SNY) collaboration deal. Related: IGM Biosciences Shares Surge After Oncology / Immunology Pact With Sanofi.…

Benzinga

GitLab Shares Pop As Analysts See Sharp Upside Post Q4

Analysts painted sharp upside to GitLab Inc (NASDAQ:GTLB) post strong Q4 results that included a notable top-line beat and FY23 guidance ahead of Street expectations. Truist analyst Joel Fishbein lowered the PT to $105 from $175 (217.2% upside) and kept a Buy, citing the change in discount rate assumptions since the IPO. KeyBanc analyst Michael Turits lowered…

Benzinga

Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ:VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trading at about 2-times cash, the stock is "undervalued" given its programs in two cancers. Devarakonda adds that the Verastem base case is supported by a…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Here's Why Roku Plunged Below 52-Week Low Today

Analysts slashed their price targets on Roku Inc (NASDAQ:ROKU) post Q4 results. Pivotal Research analyst Jeffrey Wlodarczak downgraded to Sell from Hold with a PT of $95, down from $350 (34.4% downside). The company reported an "overall mixed" Q4 as it issued a lower than forecast 2022 revenue outlook and decided to "massively ramp" operating expenses,…

Benzinga

Here's Why Piper Sandler Is Optimistic On Nvidia

Piper Sandler analyst Harsh Kumar reiterated an Overweight rating and $350 price target on NVIDIA Corp (NASDAQ:NVDA). Nvidia could be a big winner this earnings season, with profits driven by solid performance in the chip maker's gaming and data center businesses, Kumar said. "We are looking for a significant beat and raise when the company…

Benzinga

Truist Remains Bullish On Netflix; Sees Sharp Upside

Truist analyst Matthew Thornton reiterated the Buy rating and $690 price target ahead of Netflix Inc's (NASDAQ:NFLX) Q4 earnings announcement on January 20. The price target implies an upside of 34%. Sentiment on the stock is "cautious," with buy-side investors anticipating net adds as low as 6.3 million, Thornton notes. Related Content: Read How Analysts View…

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.